Safety

• BGs are not alive and pose no pathogenic threat.
• BGs present no hazard of horizontal gene transfer.
• BGs do not belong to genetically manipulated organisms (GMOs).
• BGs do not require the addition of adjuvants.

Production

• BGs are produced by fermentation.
• Compared to conventional vaccines, BGs are produced rapidly and cost-effectively.

Stability

• BGs contain the natural surface components of Gram-negative bacteria.
• BGs maintain the immunogenicity of recombinant antigens.
• BGs can be lyophilized and remain stable at ambient temperature for several years.
• Contrary to conventional vaccines, BGs do not require cooling.

Administration & Immunogenicity

• BGs are ideally suited for mucosal, needle-free immunization.
• BGs are natural adjuvants.
• BG vaccines generate a strong immune response in the recipient.

Versatility

• BGs can be generated from a variety of Gram-negative bacteria.
• BG subunit vaccines include protein and/or DNA antigens.
• BGs offer a one step production process for subunit vaccines.
• The BG vaccine platform is ideally suited for the development of vaccines against new antigens.